Steward Partners Investment Advisory LLC Acquires 64,175 Shares of Altimmune, Inc. $ALT

Steward Partners Investment Advisory LLC boosted its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 43.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 213,384 shares of the company’s stock after buying an additional 64,175 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Altimmune were worth $826,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Geneos Wealth Management Inc. purchased a new position in Altimmune in the first quarter valued at about $50,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Altimmune in the second quarter valued at $40,000. Prudential Financial Inc. purchased a new stake in Altimmune in the 2nd quarter worth approximately $43,000. E Fund Management Co. Ltd. grew its holdings in shares of Altimmune by 20.3% during the first quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $67,000 after purchasing an additional 2,268 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in Altimmune in the second quarter valued at $54,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

ALT stock opened at $4.93 on Tuesday. The company has a market capitalization of $514.41 million, a PE ratio of -4.18 and a beta of 0.01. The company’s fifty day moving average price is $4.17 and its 200-day moving average price is $4.44. Altimmune, Inc. has a one year low of $2.90 and a one year high of $10.88. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. On average, equities analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on ALT. Wall Street Zen raised Altimmune from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. B. Riley reduced their price target on Altimmune from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Altimmune in a research report on Monday, November 24th. UBS Group decreased their price target on Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, August 13th. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.83.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.